Everence Capital Management Inc Ironwood Pharmaceuticals Inc Transaction History

Everence Capital Management Inc

  • $1.54 Billion
  • Q4 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 21, 2024
BUY
$3.93 - $7.04 $29,160 - $52,236
7,420 Added 36.32%
27,850 $115,000
Q3 2023

Oct 16, 2023
BUY
$8.25 - $11.35 $85,305 - $117,359
10,340 Added 102.48%
20,430 $197,000
Q1 2023

Apr 04, 2023
SELL
$10.37 - $12.56 $362,535 - $439,097
-34,960 Reduced 77.6%
10,090 $106,000
Q4 2022

Jan 31, 2023
SELL
$9.9 - $12.43 $93,456 - $117,339
-9,440 Reduced 17.32%
45,050 $558,000
Q2 2022

Jul 26, 2022
BUY
$11.05 - $12.72 $602,114 - $693,112
54,490 New
54,490 $628,000

Others Institutions Holding IRWD

# of Institutions
231
Shares Held
162M
Call Options Held
11.2M
Put Options Held
9.1K
View Full List

About IRONWOOD PHARMACEUTICALS INC

IRWD Quotes by TradingView
  • Ticker IRWD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 153,231,008
  • Market Cap $570M
  • Description
  • Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...
More about IRWD
Track This Portfolio

Track Everence Capital Management Inc Portfolio

Follow Everence Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Everence Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Everence Capital Management Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email